{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000462","form_type":"8-K","ticker":"OM","cik":"0001484612","company_name":"Outset Medical, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.193013+00:00","generated_at":"2026-06-20T17:43:55.526296+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Outset Medical reports Q4 2022 expected revenue ~$31.5M; guides FY2023 revenue $140-150M","bullets":["Q4 2022 expected revenue ~$31.5M (+13% QoQ); FY2022 expected revenue ~$115M (+12% YoY).","Installed base of Tablo systems grew 54% YoY to ~4,000; home provider units doubled to ~800.","FY2022 non-GAAP gross margin expected in mid-teens; FY2023 guidance: ~20% full year, mid-20% exit Q4.","2023 revenue guidance $140M-$150M (22-30% growth over 2022 expected revenue)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000462","json":"https://secwatch.observer/filing/0000950170-23-000462.json","markdown":"https://secwatch.observer/filing/0000950170-23-000462.md","text":"https://secwatch.observer/filing/0000950170-23-000462.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023000462/0000950170-23-000462-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023000462/om-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:43:55.526296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03b196692e0b7d1e267c110b0e884edf8fd3b861","claim":"Outset Medical, Inc. updated its 2023 guidance (initiated).","evidence_excerpt":"Outset expects 2023 revenue to be between $140 million to $150 million, growing approximately 22% to 30% over expected revenue for 2022. Non-GAAP gross margin is expected to expand to approximately 20% for the full year 2023 and exit the year in the mid-20% range for the fourth quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023000462/0000950170-23-000462-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"08175209c3ebd99e2dd2760ffa9be9cc371f3096","claim":"Outset Medical, Inc. reported the fourth quarter and fiscal year ended December 31, 2022 results: revenue approximately $31.5 million.","evidence_excerpt":"revenue for the fourth quarter and fiscal year ended December 31, 2022. Fourth Quarter and Year End Highlights • Revenue in the fourth quarter is expected to be approximately $31.5 million, a 13% increase compared to $27.8 million in the third quarter of 2022 • Revenue for 2022 is expected to be approximately $115 million, a 12% increase compared to $102.6 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023000462/0000950170-23-000462-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2022"},{"label":"Revenue","value":"approximately $31.5 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}